Radar · Life Sciences in New York
Best Life Sciences Companies in New York, United States
The 1140 best Life Sciences companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Immunovant.
By Riya SenguptaFinancials
1140companies tracked
$19.3Bdisclosed funding
5unicorns
562have raised
FLIAR INTELLIGENCE · LIFE SCIENCES × NEW YORK
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
164companies analysed
83%cloud-native stacks
2025funding peak (by rounds)
7unicorns
2016median founding year
380kcombined LinkedIn audience
32%of audience held by top 3
7companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in New York
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunovant Provider of therapeutics solutions for treating autoimmune diseases 29Funding top 16%News top 45%Moat top 48%Tech bottom 48% All 7 signals ▾Fundingtop 16% Newstop 45% Moattop 48% Techbottom 48% Growthbottom 47% Globalbottom 41% Marketbottom 25% Funding: Raised $685M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) News: 7 BI events in 12 mo (of 46 tracked, 7 types) · -50% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $685M | 17 mo ago | Public | 1 | — | — | — |
| 2 | Immunic Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases 35Funding top 19%Tech top 41%Moat top 48%Growth top 50% All 9 signals ▾Fundingtop 19% Techtop 41% Moattop 48% Growthtop 50% Talentbottom 49% Globalbottom 45% Newsbottom 40% Marketbottom 38% Fin. healthbottom 20% Funding: Raised $560M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) Tech: 34 technologies across 3/8 capability areas · Cloud: Cloudflare, Google Cloud rank vs industry peers · Fliar Intelligence Index 35/100 | $560M | 4 mo ago | Public | 77 77 → 91 (+18%) · sector median +14% | Daniel Vitt Chief Executive Officer | — | — |
| 3 | Delcath Speciality Pharmaceutical and medical device company focused on oncology 74Product top 14%Funding top 20%Fin. health top 31%Innovation top 34% All 10 signals ▾Producttop 14% Fundingtop 20% Fin. healthtop 31% Innovationtop 34% Techtop 37% Growthtop 39% Markettop 43% Moattop 47% Newstop 48% Globalbottom 44% Product: 5 distinct product lines · Company stage: Public Funding: Raised $307M across 19 rounds · 19 rounds over 24 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 74/100 | $307M | 17 mo ago | Public | 52 | — | — | — |
| 4 | Opentrons 🦄 Developer of pipetting robot for lab automation 84Funding top 18%Market top 26%Moat top 26%Growth top 31% All 8 signals ▾Fundingtop 18% Markettop 26% Moattop 26% Growthtop 31% Techtop 32% Globaltop 37% Talenttop 38% Newstop 44% Funding: Raised $241M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) Market: 177 employees (top 6% of Life Sciences Platforms and Tools) · Top-1,000,000 web property rank vs industry peers · Fliar Intelligence Index 84/100 | $241M | 6 mo ago | Series C | 177 177 → 196 (+11%) · sector median +14% | James Atwood CEO | — | 3 launchs |
| 5 | LEXEO Therapeutics Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases 29Funding top 19%News top 43%Growth top 47%Tech bottom 49% All 9 signals ▾Fundingtop 19% Newstop 43% Growthtop 47% Techbottom 49% Talentbottom 40% Globalbottom 39% Marketbottom 31% Moatbottom 31% Fin. healthbottom 29% Funding: Raised $185M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) News: 7 BI events in 12 mo (of 27 tracked, 4 types) · -36% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $185M | 7 mo ago | Public | 58 58 → 97 (+67%) · sector median +14% | Nolan Townsend CEO | — | 1 launch |
| 6 | Precision Neuroscience Developed of brain-computer interface tool for medical treatment and drug development 50Funding top 18%Moat top 31%Talent top 38%Tech top 39% All 9 signals ▾Fundingtop 18% Moattop 31% Talenttop 38% Techtop 39% AItop 45% Growthbottom 40% Globalbottom 37% Marketbottom 34% Newsbottom 18% Funding: Raised $174M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 50/100 | $174M | 7 mo ago | Series C | 22 | Benjamin Rapoport Co-Founder & CSO | — | 1 job opening · 2 launchs · 1 award |
| 7 | Synchron Developer of implantable bioelectronics for the treatment of neurological conditions 48Funding top 17%News top 30%Talent top 38%Growth top 47% All 8 signals ▾Fundingtop 17% Newstop 30% Talenttop 38% Growthtop 47% Moattop 48% Marketbottom 46% Globalbottom 39% Techbottom 35% Funding: Raised $145M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) News: 3 BI events in 12 mo (of 14 tracked, 7 types) · Top themes: Funding, Capital raise rank vs industry peers · Fliar Intelligence Index 48/100 | $145M | 7 mo ago | Series D | 53 53 → 130 (+145%) · sector median +14% | Rahul Sharma Co-Founder | — | 2 job openings |
| 8 | LB Pharmaceuticals Developer of small molecule based therapeutics for schizophrenia 67Moat top 21%Growth top 23%Patents top 25%News top 27% All 10 signals ▾Moattop 21% Growthtop 23% Patentstop 25% Newstop 27% Fundingtop 30% Innovationtop 34% Talenttop 41% Marketbottom 44% Globalbottom 43% Partnersbottom 35% Moat: Editorial + unicorn rating 7/10 · IP moat: 437 patents Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 67/100 | $130M | 4 mo ago | Public | — | Zachary Prensky Founder & CEO | 437 patents Small-molecule immunomodulators targeting CXCR4/CXCR2, BTK, complement, and IL-6 pathways | — |
| 9 | Applied DNA Sciences Developer of botanical-DNA based security and authentication solutions 24Funding top 24%Product top 24%Tech top 40%Innovation bottom 48% All 10 signals ▾Fundingtop 24% Producttop 24% Techtop 40% Innovationbottom 48% Globalbottom 37% Marketbottom 36% Newsbottom 35% Moatbottom 33% Fin. healthbottom 29% Growthbottom 25% Funding: Raised $98.6M across 17 rounds · 17 rounds over 21 yrs (0.8/yr) Product: 1 product launch event in 12 mo · 7 distinct product lines rank vs industry peers · Fliar Intelligence Index 24/100 | $99M | 8 mo ago | Public | 55 55 → 49 (-11%) · sector median +14% | — | — | — |
| 10 | Excelsior Sciences Developer of chemistry for automated small molecule discovery and manufacturing 72Funding top 21%Talent top 38%AI top 45%Global bottom 48% All 4 signals ▾Fundingtop 21% Talenttop 38% AItop 45% Globalbottom 48% Funding: Raised $95.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 72/100 | $95M | 6 mo ago | Series A | — | Michael Foley Co-Founder and Chief Executive Officer | — | — |
| 11 | Volastra Developer of therapeutics for cancer treatment 40Funding top 24%Talent top 28%Moat top 39%Tech bottom 48% All 6 signals ▾Fundingtop 24% Talenttop 28% Moattop 39% Techbottom 48% Globalbottom 37% Marketbottom 31% Funding: Raised $87.2M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 40/100 | $87M | 9 mo ago | Series B | 21 21 → 41 (+95%) · sector median +14% | Samuel Bakhoum Co-Founder | — | 1 job opening |
| 12 | Proxima Developer of a platform for programmable protein interaction-based drug discovery 42Funding top 24%Talent top 38%AI top 45%Tech bottom 45% All 6 signals ▾Fundingtop 24% Talenttop 38% AItop 45% Techbottom 45% Globalbottom 33% Marketbottom 31% Funding: Raised $86.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 42/100 | $86M | 5 mo ago | Seed | — | Luca Naef Co-Founder & CTO | — | — |
| 13 | Leal Therapeutics Developer of therapeutics to treat neurological diseases 32Funding top 21%Moat top 42%Talent bottom 49%Market bottom 36% All 5 signals ▾Fundingtop 21% Moattop 42% Talentbottom 49% Marketbottom 36% Globalbottom 29% Funding: Raised $84.0M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 32/100 | $84M | 9 mo ago | Series A | 25 | Asa Abeliovich Founder & CEO | — | — |
| 14 | Rocket Pharma Developer of gene-modified cell therapies for the treatment of rare diseases 60Funding top 24%Tech top 32%Market top 42%News top 46% All 7 signals ▾Fundingtop 24% Techtop 32% Markettop 42% Newstop 46% Moattop 48% Growthtop 50% Globalbottom 32% Funding: Raised $83.2M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Tech: 54 technologies across 5/8 capability areas · Cloud: Akamai, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 60/100 | $83M | 17 mo ago | Public | 268 268 → 222 (-17%) · sector median +14% | — | — | 1 internship |
| 15 | Gilgamesh Developer of drugs for neuropsychiatric conditions 62Growth top 15%Funding top 17%Talent top 23%News top 28% All 9 signals ▾Growthtop 15% Fundingtop 17% Talenttop 23% Newstop 28% Moattop 39% AItop 45% Techbottom 40% Globalbottom 39% Marketbottom 21% Growth: Fresh capital in last 24 mo Funding: Raised $83.1M across 13 rounds · 13 rounds over 6 yrs (2.2/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $83M | 2 mo ago | Series B | 2 | Jonathon Sporn Co-Founder & CEO | — | — |
| 16 | Cresilon Developer of hemostatic products for wound care 60Funding top 22%Growth top 32%Moat top 32%Product top 35% All 10 signals ▾Fundingtop 22% Growthtop 32% Moattop 32% Producttop 35% Techtop 37% Patentstop 42% Innovationtop 48% Marketbottom 46% Globalbottom 36% Newsbottom 18% Funding: Raised $81.7M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Growth: Headcount 53 → 73 (+38%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $82M | 1 mo ago | Series B | 73 | — | 40 patents Hemostatic polymer adhesives and delivery devices for rapid surgical bleeding control | — |
| 17 | Intra-Cellular Therapies Developer of therapeutics for psychiatric and neurologic diseases 78Patents top 20%Moat top 23%Funding top 26%Market top 27% All 11 signals ▾Patentstop 20% Moattop 23% Fundingtop 26% Markettop 27% Fin. healthtop 27% Innovationtop 29% Producttop 36% Growthtop 40% Techbottom 46% Globalbottom 42% Newsbottom 23% Patents: 1,493 patents matched (strict assignee match) · 508 filings since 2022 vs 551 in 2017-21 Moat: Top 11% by revenue among 18 tracked Neurology companies · Editorial + unicorn rating 6/10 rank vs industry peers · Fliar Intelligence Index 78/100 | $81M | 13 mo ago | Acquired | 610 610 → 639 (+5%) · sector median +14% | — | 1,493 patents Novel heterocyclic small‑molecule therapeutics, especially deuterated CNS drug candidates. | — |
| 18 | Nanit Provider of smart baby monitoring systems with sleep and breathing analysis 74Funding top 19%Tech top 20%Moat top 24%Talent top 28% All 10 signals ▾Fundingtop 19% Techtop 20% Moattop 24% Talenttop 28% Producttop 30% Markettop 36% Customerstop 37% Growthbottom 47% Globalbottom 43% Newsbottom 33% Funding: Raised $75.0M across 5 rounds · 5 rounds over 10 yrs (0.5/yr) Tech: 73 technologies across 6/8 capability areas · Cloud: Amazon Cloudfront, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 74/100 | $75M | 6 mo ago | Series D | 111 | Andrew Berman Co-Founder | — | 3 launchs · 1 award |
| 19 | Elysium Developer and manufactures of cellular health supplements 53Tech top 24%Funding top 28%Moat top 31%Growth top 35% All 11 signals ▾Techtop 24% Fundingtop 28% Moattop 31% Growthtop 35% Producttop 45% Marketbottom 49% Talentbottom 49% Globalbottom 39% Innovationbottom 31% Patentsbottom 29% Newsbottom 27% Tech: 72 technologies across 5/8 capability areas · Cloud: Amazon S3, Amazon Ses Funding: Raised $71.2M across 7 rounds · 7 rounds over 10 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $71M | 12 mo ago | Series C | — | Dan Alminana Founder & COO | 6 patents Patents concentrated in transport & manufacturing processes | — |
| 20 | Tandem AI AI-based drug discovery tool for researchers 62Funding top 27%Moat top 32%Patents top 33%Talent top 38% All 10 signals ▾Fundingtop 27% Moattop 32% Patentstop 33% Talenttop 38% Innovationtop 41% Newstop 44% AItop 45% Marketbottom 49% Techbottom 46% Globalbottom 37% Funding: Raised $60.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 34 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $60M | 7 mo ago | Series A | 200 | Jeff He Co-Founder & CEO | 34 patents Optimized photovoltaic modules with parameter matching and UV filtering for solar power systems | 1 job opening · 1 launch |
| 21 | ILiAD Biotechnologies Developer of immunity-inducing vaccine for the prevention and treatment of pertussis 24Funding top 25%Moat top 36%Patents top 38%Innovation top 42% All 9 signals ▾Fundingtop 25% Moattop 36% Patentstop 38% Innovationtop 42% Newsbottom 49% Talentbottom 49% Globalbottom 36% Marketbottom 24% Techbottom 22% Funding: Raised $51.2M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 24/100 | $51M | 4 mo ago | Series B | 8 | Keith Rubin Founder & CEO | 24 patents Patents concentrated in health & consumer products | 1 partnership |
| 22 | Manas AI Provider of a platform for drug discovery for the treatment of cancer and rare diseases 62Funding top 24%Growth top 35%Tech top 42%AI top 45% All 7 signals ▾Fundingtop 24% Growthtop 35% Techtop 42% AItop 45% Talentbottom 49% Globalbottom 48% Marketbottom 40% Funding: Raised $50.6M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 62/100 | $51M | 8 mo ago | Seed | — | Siddhartha Mukherjee Co-Founder & CEO | — | — |
| 23 | Qlaris Bio Provides AI-based technology for treating ophthalmic diseases 35Funding top 29%AI top 45%Tech top 48%Moat top 48% All 7 signals ▾Fundingtop 29% AItop 45% Techtop 48% Moattop 48% Talenttop 50% Globalbottom 36% Marketbottom 25% Funding: Raised $49.0M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) AI: Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 35/100 | $49M | 7 mo ago | Series B | 9 | Thurein Htoo Chief Executive Officer & Co-Founder | — | — |
| 24 | Codagenix Developer of live-attenuated viral vaccines using proprietary SAVE technology 62Patents top 19%Moat top 21%Innovation top 24%Talent top 28% All 9 signals ▾Patentstop 19% Moattop 21% Innovationtop 24% Talenttop 28% Fundingtop 30% Marketbottom 49% Globalbottom 42% Techbottom 38% Newsbottom 27% Patents: 127 patents matched (strict assignee match) · 91 filings since 2022 vs 36 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 127 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $47M | 14 mo ago | Series B | 41 | — | 127 patents Live-attenuated viral vaccine design using codon deoptimization and recombinant virus platforms | — |
| 25 | Peerbridge Health Developer of ambulatory ECG system with AI-enabled cardiac diagnostics 42Innovation top 23%Funding top 27%Product top 30%Moat top 39% All 7 signals ▾Innovationtop 23% Fundingtop 27% Producttop 30% Moattop 39% Techtop 48% Globalbottom 37% Marketbottom 19% Innovation: 4 product lines · Deep-tech classification: Tech Hardware Funding: Raised $46.1M across 14 rounds · 14 rounds over 11 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $46M | 13 mo ago | Series B | 3 | — | — | 1 launch · 1 expansion |
| 26 | Epibone Developer of patient‑specific bone and cartilage grafts 50Moat top 25%Talent top 28%Funding top 29%Patents top 32% All 9 signals ▾Moattop 25% Talenttop 28% Fundingtop 29% Patentstop 32% Innovationtop 38% Techtop 46% Globalbottom 42% Marketbottom 31% Newsbottom 21% Moat: Editorial + unicorn rating 7/10 · IP moat: 48 patents Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 50/100 | $44M | 9 mo ago | Series B | 34 | Elisa Cimetta Co-Founder | 48 patents Regenerative orthopedic biomaterials for injectable cartilage/tendon/ligament repair and surgical tools. | — |
| 27 | Indaptus Developer of immunotherapies for oncology and infectious diseases 19Funding top 35%Moat top 39%Talent bottom 49%Growth bottom 42% All 7 signals ▾Fundingtop 35% Moattop 39% Talentbottom 49% Growthbottom 42% Globalbottom 30% Marketbottom 24% Newsbottom 23% Funding: Raised $37.9M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Moat: Editorial + unicorn rating 6/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 19/100 | $38M | 12 mo ago | Public | 6 | Jeffrey Meckler Chief Executive Officer | — | — |
| 28 | IN8Bio Provider of immune based therapies for the treatment of cancer 50Funding top 27%Patents top 32%Moat top 38%Innovation top 39% All 10 signals ▾Fundingtop 27% Patentstop 32% Moattop 38% Innovationtop 39% Techtop 41% Newstop 42% Growthtop 45% Talentbottom 41% Marketbottom 39% Globalbottom 36% Funding: Raised $35.0M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) Patents: 33 patents matched (strict assignee match) · 25 filings since 2022 vs 8 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $35M | 5 mo ago | Public | 31 31 → 25 (-19%) · sector median +14% | William Ho Founder & CEO | 33 patents Engineered gamma‑delta T‑cell CAR immunotherapies for cancer treatment | — |
| 29 | PreciseDx Provider of an AI-based medical image analysis software for healthcare professionals 48Talent top 23%AI top 30%Funding top 32%Moat top 48% All 8 signals ▾Talenttop 23% AItop 30% Fundingtop 32% Moattop 48% Growthbottom 42% Globalbottom 37% Marketbottom 32% Newsbottom 18% Talent: 5 named leaders on record · 5 C-suite/founder profiles curated AI: Classified as an AI company · Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 48/100 | $32M | 12 mo ago | Series B | 12 | Michael Donovan Co-Founder | — | — |
| 30 | Atommap Provider of physics-based and ML-augmented computational drug discovery platform 65Funding top 28%Talent top 35%Global bottom 25% All 3 signals ▾Fundingtop 28% Talenttop 35% Globalbottom 25% Funding: Raised $31.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 3 named leaders on record rank vs industry peers · Fliar Intelligence Index 65/100 | $31M | 3 mo ago | Series C | — | Yujie Wu Co-Founder & CTO | — | — |
| 31 | Valthos Developer of AI systems for biological threat identification and countermeasure design 55Funding top 34%AI top 45%Talent bottom 49%Global bottom 33% All 4 signals ▾Fundingtop 34% AItop 45% Talentbottom 49% Globalbottom 33% Funding: Raised $30.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) AI: Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 55/100 | $30M | 10 mo ago | Seed | — | Tess Stekelenburg Co-Founder & President | — | — |
| 32 | Kanvas Biosciences Provider of imaging solutions for microbial research and infectious diseases 27Funding top 27%Talent top 38%Global bottom 38%Moat bottom 38% All 5 signals ▾Fundingtop 27% Talenttop 38% Globalbottom 38% Moatbottom 38% Marketbottom 27% Funding: Raised $29.5M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 27/100 | $30M | 1 mo ago | Series A | 10 | Iwijn De Vlaminck Co-Founder | — | 1 expansion |
| 33 | Iantrek Developer of a minimally invasive eye surgery technology 60Growth top 15%News top 22%Innovation top 27%Patents top 27% All 9 signals ▾Growthtop 15% Newstop 22% Innovationtop 27% Patentstop 27% Fundingtop 29% Moattop 36% Talentbottom 49% Globalbottom 40% Marketbottom 21% Growth: Fresh capital in last 24 mo News: 6 BI events in 12 mo (of 10 tracked, 3 types) · +200% YoY rank vs industry peers · Fliar Intelligence Index 60/100 | $23M | 1 mo ago | Series C | 2 | Sean Ianchulev Founder & CEO | 62 patents Glaucoma treatment via biologic intraocular stents and aqueous drainage devices | 1 job opening · 1 launch |
| 34 | MEND Provider of dietary supplements to manage body immunity power 42Funding top 33%Growth top 35%Talent top 38%Moat top 48% All 7 signals ▾Fundingtop 33% Growthtop 35% Talenttop 38% Moattop 48% Techtop 49% Globalbottom 37% Marketbottom 27% Funding: Raised $20.3M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 42/100 | $20M | 4 mo ago | Series A | 10 | Eziah Syed Co-Founder & Chief of Growth & Innovation | — | 1 job opening · 1 launch · 1 partnership |
| 35 | ZetaGen Developer of targeted therapies for metastatic and primary breast cancers 27Talent top 15%Funding top 33%Moat top 48%Tech bottom 34% All 6 signals ▾Talenttop 15% Fundingtop 33% Moattop 48% Techbottom 34% Globalbottom 32% Marketbottom 25% Talent: Analyst team rating 5/5 Funding: Raised $20.3M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) rank vs industry peers · Fliar Intelligence Index 27/100 | $20M | 7 mo ago | Series B | 9 | — | — | — |
| 36 | BioRestorative Therapies Developer of stem cell therapies to address multiple diseases 27News top 24%Moat top 32%Funding top 33%Patents top 42% All 11 signals ▾Newstop 24% Moattop 32% Fundingtop 33% Patentstop 42% Growthtop 43% Techtop 45% Innovationbottom 48% Globalbottom 41% Talentbottom 40% Fin. healthbottom 26% Marketbottom 21% News: 9 BI events in 12 mo (of 27 tracked, 6 types) · +80% YoY Moat: Editorial + unicorn rating 4/10 · IP moat: 45 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $20M | 8 mo ago | Public | 10 10 → 21 (+110%) · sector median +14% | Lance Alstodt Chairman and CEO | 45 patents Patents concentrated in chemistry & materials | — |
| 37 | Dandelion Health Provider of AI-powered real-world data platform for clinical development 37Talent top 28%Funding top 34%Moat top 39%AI top 45% All 6 signals ▾Talenttop 28% Fundingtop 34% Moattop 39% AItop 45% Globalbottom 37% Marketbottom 24% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $15.9M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $16M | 1 mo ago | Series A | 7 | Elliott Green Co-Founder & CEO | — | 1 partnership |
| 38 | ProofPilot Platform for the development & execution of research studies 48Product top 26%Talent top 28%Innovation top 38%Moat top 39% All 9 signals ▾Producttop 26% Talenttop 28% Innovationtop 38% Moattop 39% Fundingtop 41% Techbottom 47% Marketbottom 38% Globalbottom 36% Newsbottom 17% Product: 3 distinct product lines · Company stage: Series D Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 48/100 | $16M | 9 mo ago | Series D | 19 | — | — | 1 launch |
| 39 | Jan Biotech Provider of diagnostic assays for the detection of infectious diseases 10Funding top 42%Talent bottom 45%Tech bottom 34%Global bottom 29% All 5 signals ▾Fundingtop 42% Talentbottom 45% Techbottom 34% Globalbottom 29% Marketbottom 14% Funding: Raised $13.4M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) Talent: 1 named leader on record rank vs industry peers · Fliar Intelligence Index 10/100 | $13M | 9 mo ago | Funding Raised | 6 | Jennifer Nichols President/Co-Founder | — | — |
| 40 | Coridea Medical device incubator creating innovative solutions for cardiology, pulmonary, and renal patients 7Funding top 38%Moat top 45%Global bottom 43%Patents bottom 30% All 6 signals ▾Fundingtop 38% Moattop 45% Globalbottom 43% Patentsbottom 30% Marketbottom 21% Innovationbottom 21% Funding: Raised $12.5M across 14 rounds · 14 rounds over 15 yrs (0.9/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 5 patents rank vs industry peers · Fliar Intelligence Index 7/100 | $12M | 9 mo ago | Series A | 9 | — | 5 patents Patents concentrated in health & consumer products | — |
| 41 | Bond Biosciences Therapeutics for ion-related diseases using non-absorbed oral treatments 10Funding top 36%Talent top 38%Global bottom 29%Market bottom 11% All 4 signals ▾Fundingtop 36% Talenttop 38% Globalbottom 29% Marketbottom 11% Funding: Raised $11.8M · 6 rounds over 6 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 10/100 | $12M | 2 mo ago | Series B | 4 | Cory Berkland Co-Founder & CEO | — | — |
| 42 | Hexem bio Developer of stem cell-based therapies for aging and disease prevention 29Talent top 28%Funding top 41%Global top 45%Tech bottom 43% All 5 signals ▾Talenttop 28% Fundingtop 41% Globaltop 45% Techbottom 43% Marketbottom 25% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $10.4M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $10M | 2 mo ago | Seed | — | Mo Ebrahimkhani Co-Founder | — | — |
| 43 | Climatic Developer of a respiratory device designed to improve lung health 35Talent top 38%Funding top 39%Tech bottom 37%Global bottom 33% All 4 signals ▾Talenttop 38% Fundingtop 39% Techbottom 37% Globalbottom 33% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $10.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $10M | 4 mo ago | Seed | — | Margaret Wishingrad Co-Founder | — | 2 launchs · 1 award |
| 44 | IBS Developer of fingerprint drug testing and sweat drug monitoring solutions 42Innovation top 23%Product top 35%Funding top 42%News top 42% All 10 signals ▾Innovationtop 23% Producttop 35% Fundingtop 42% Newstop 42% Techtop 45% Talentbottom 49% Growthbottom 47% Fin. healthbottom 34% Marketbottom 33% Globalbottom 30% Innovation: 4 new-product events in 24 mo · Deep-tech classification: Tech Hardware Product: 0 product launch events in 12 mo, 4 the year before · Company stage: Public rank vs industry peers · Fliar Intelligence Index 42/100 | $10M | 5 mo ago | Public | 26 | Harry Simeonidis President and CEO IBS Inc | — | — |
| 45 | Sequential Bio Provider of in-vivio microbiome testing platform for skin care 48Funding top 35%Growth top 35%Talent top 38%Moat top 44% All 7 signals ▾Fundingtop 35% Growthtop 35% Talenttop 38% Moattop 44% Techtop 45% Globaltop 50% Marketbottom 30% Funding: Raised $6.4M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $6M | 3 mo ago | Series A | — | Oliver Worsley Co-Founder & CEO | — | — |
| 46 | Ancilia Developer of microbiome therapies for immunology and oncology indications 19Funding top 37%Patents top 41%Innovation bottom 49%Moat bottom 49% All 7 signals ▾Fundingtop 37% Patentstop 41% Innovationbottom 49% Moatbottom 49% Globalbottom 43% Marketbottom 20% Newsbottom 18% Funding: Raised $4.2M across 6 rounds · 6 rounds over 2 yrs (3.0/yr) Patents: 11 patents matched (strict assignee match) · 9 filings since 2022 vs 2 in 2017-21 rank vs industry peers · Fliar Intelligence Index 19/100 | $4M | 4 mo ago | Series B | 5 | — | 11 patents Blockchain security analytics and microbiome modulation therapeutics | — |
| 47 | Cloud Provider of cloud-based remote cardiology vital signs monitoring devices and platforms 67Growth top 21%Innovation top 22%Patents top 23%Moat top 32% All 11 signals ▾Growthtop 21% Innovationtop 22% Patentstop 23% Moattop 32% Fundingtop 35% Fin. healthtop 38% Producttop 39% Techbottom 48% Globalbottom 46% Newsbottom 40% Marketbottom 37% Growth: Revenue +701% YoY · Fresh capital in last 24 mo Innovation: 85 patents (top 21% of patent-holders) · 23 filings since 2022 vs 14 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $3M | 2 mo ago | Public | 55 | — | 85 patents Remote health monitoring, biomedical AR, and networked fax/telemedicine data transmission | — |
| 48 | Inso Bio Developer of a microfluidic-based automated device used for sample preparation 13Talent top 38%Funding top 47%Global bottom 39%Market bottom 18% All 4 signals ▾Talenttop 38% Fundingtop 47% Globalbottom 39% Marketbottom 18% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated Funding: Raised $2.8M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) rank vs industry peers · Fliar Intelligence Index 13/100 | $3M | 3 mo ago | Seed | 4 | Harvey Tian Co-Founder & CEO | — | — |
| 49 | Stratum Biosciences Provider of AI-based solutions for dermatological therapies and molecular delivery across the skin 50Talent top 38%AI top 45%Funding bottom 46%Global bottom 33% All 4 signals ▾Talenttop 38% AItop 45% Fundingbottom 46% Globalbottom 33% Talent: 2 named leaders on record · 2 C-suite/founder profiles curated AI: Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 50/100 | $2M | 2 mo ago | Seed | — | Ross Pearlman Co-Founder & CEO | — | 1 partnership · 1 expansion |
| 50 | Reme-D.Inc Developer of diagnostic kits for both human and animal diseases 27Patents top 30%Global top 38%Innovation top 41%Funding top 44% All 7 signals ▾Patentstop 30% Globaltop 38% Innovationtop 41% Fundingtop 44% Talentbottom 49% Techbottom 30% Marketbottom 25% Patents: 42 patents matched (strict assignee match) · 10 filings since 2022 vs 6 in 2017-21 Global: Patents filed in 3 jurisdictions · Investors from 3 countries beyond United States rank vs industry peers · Fliar Intelligence Index 27/100 | $2M | 2 mo ago | Seed | — | Salma Tammam Founder & CEO | 42 patents Hydraulic control valves and pistons for rotary steerable drilling tools | — |
Top 12 Life Sciences companies in New York
#1
Public · New York City, New York · founded 2003 · 77 employees$559.7Mraised▾
Public · New York City, New York · founded 2003 · 77 employees
Developer of oral immunology therapies for treating chronic inflammatory and autoimmune diseases. The product pipeline of the company includes vidofludimus calcium (IMU-838), a selective immune modulator for multiple sclerosis, IMU-935, a selective inverse agonist targeted for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome and IMU-856, for bowel barrier dysfunction.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 19%Tech
top 41%Moat
top 48%Growth
top 50%Talent
bottom 49%Global
bottom 45%Funding: Raised $560M across 4 rounds · 4 rounds over 10 yrs (0.4/yr) · Last round Post IPO (Feb 2026)
Tech: 34 technologies across 3/8 capability areas · Cloud: Cloudflare, Google Cloud · Security: Cloudflare Bot Management, Hsts
Moat: Editorial + unicorn rating 4/10 · 10 curated direct competitors tracked
Audience (LinkedIn): 12k LinkedIn followers — 3.2% of this cohort's audience
Funding rounds
- Feb 2026Post IPO$400M
- Jan 2024Post IPO$80M
- Oct 2022Post IPO$60M
- Sep 2016Post IPO$19.7M
Founders & team
Investors
BVF Partners, Janus Henderson Investors, Soleus Capital, RTW Investments, Adage Capital Management, Avidity Partners
Tech stack
Apache Http ServerBricksCloudflareCloudflare Bot ManagementCookiebotCore-Js
#2
Series B · New York City, New York · founded 2010 · 73 employees$81.7Mraised▾
Series B · New York City, New York · founded 2010 · 73 employees
Developer of hemostatic products for wound care. The company offers VETIGEL Hemostatic Gel(a prescription hemostatic gel kit for animal use only. It can stop moderate to severe bleeds in animals), and TRAUMAGEL a hemostatic device for temporary use to control external traumatic bleeding not amenable to tourniquet application.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 22%Growth
top 32%Moat
top 32%Product
top 35%Tech
top 37%Patents
top 42%Funding: Raised $81.7M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) · Last round Series B (Apr 2026)
Growth: Headcount 53 → 73 (+38%) across vintages · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 7/10 · IP moat: 40 patents · 9 curated direct competitors tracked
Funding rounds
- Apr 2026Series B$5M
- Nov 2025Series B$6.7M
- Apr 2024Series B$25M
- Aug 2023Series A$17.2M
Investors
Paulson Investment, Valued ventures, Hammerstone Capital, PKJ Ventures, IMEX VP Investment Group, Design Technologies
Tech stack
Apple Icloud MailAstraCdnjsCloudflareCloudflare Bot ManagementCookieyes
#3
Series B · New York City, New York · founded 2019 · 2 employees$83.1Mraised▾
Series B · New York City, New York · founded 2019 · 2 employees
Developer of drugs for neuropsychiatric conditions. The company has an AI-powered discovery and translational platform to develop novel psychotropic drugs for the treatment of neuropsychiatric conditions including depression, anxiety, substance use, and stress-related disorders. Products include GM-1020 and GM-2505 an oral NMDAR Antagonist.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Growth
top 15%Funding
top 17%Talent
top 23%News
top 28%Moat
top 39%AI
top 45%Growth: Fresh capital in last 24 mo
Funding: Raised $83.1M across 13 rounds · 13 rounds over 6 yrs (2.2/yr) · Last round Series B (Mar 2026)
Talent: 5 named leaders on record · 5 C-suite/founder profiles curated
Audience (LinkedIn): 11k LinkedIn followers — 3.0% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: CMC - Drug Substance professional
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. AbbVie) announced in 12 mo
Funding rounds
- Mar 2026Series B$2.2M
- Mar 2026Series B$60M
- Jan 2026Series B$6.1M
- May 2025Grant (prize money)$5.4M
Founders & team
Investors
Prime Movers Lab, Noetic Psychedelic Fund, Gron Ventures, Route 66 Ventures, JLS Fund, Palo Santo
Tech stack
CloudflareGoogle AnalyticsGoogle Font ApiGoogle Hosted LibrariesHstsHttp/3
#4
Public · New York City, New York · founded 2015$130.1Mraised▾
Public · New York City, New York · founded 2015
Developer of small molecule based therapeutics for schizophrenia. The company's lead product candidate LB-102, also known as N-methyl amisulpride, is very similar to the marketed antipsychotic amisulpride and differs by only one methyl group (CH3). The drug acts as an antagonist to dopamine (D2, D3), and 5-HT7 receptors and exerts the antipsychotic effect.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Moat
top 21%Growth
top 23%Patents
top 25%News
top 27%Funding
top 30%Innovation
top 34%Moat: Editorial + unicorn rating 7/10 · IP moat: 437 patents
Growth: 1 acquisition/expansion move in 24 mo · Fresh capital in last 24 mo
Patents: 437 patents matched (strict assignee match) · 172 filings since 2022 vs 251 in 2017-21 · Latest publication 2026
Funding rounds
- Feb 2026Post IPO$100M
- Aug 2023Series C$110.7M
- Aug 2020Series B$10M
- Mar 2019Series A$1.6M
Founders & team
Investors
Tarnagulla Ventures
#5
Series C · Brooklyn, New York · founded 2013 · 177 employees$240.6Mraised▾
Series C · Brooklyn, New York · founded 2013 · 177 employees
Developer of pipetting robot for lab automation. The company's product OT-2 personal pipetting robot uses manual micro-pipettes to transfer fluids and automates the repetitive benchwork associated with lab activities. It also has scalable hardware and software and is developed in an open-source manner.
Fliar Intelligence Index™ 84how this company ranks against its industry peers
Funding
top 18%Market
top 26%Moat
top 26%Growth
top 31%Tech
top 32%Global
top 37%Funding: Raised $241M across 6 rounds · 6 rounds over 12 yrs (0.5/yr) · Last round Series C (Nov 2025)
Market: 177 employees (top 6% of Life Sciences Platforms and Tools) · Top-1,000,000 web property · Unicorn (valued $1.8B)
Moat: Editorial + unicorn rating 9/10 · Unicorn · 9 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 6.4% of this cohort's audience
Activity (LinkedIn): 3 product launches announced in 12 mo
Funding rounds
- Nov 2025Series C$20.1M
- Sep 2021Series C$200M
- Aug 2020Series B$20.6M
- Nov 2019Seed$2.2M
Founders & team
Investors
HAX, Khosla Ventures, Y Combinator, Lerer Hippeau, SoftBank Group, Sands Capital
Tech stack
AlgoliaAlpine.JsAmazon S3Amazon Web ServicesApple Icloud MailBigcommerce
#6
Public · New York City, New York · founded 2018 · 58 employees$185Mraised▾
Public · New York City, New York · founded 2018 · 58 employees
Developer of gene therapy for the treatment of CLN2 Batten and Alzheimer's diseases. It has developed a lead candidate LX1001 APOE4 inhibitor that helps in treating Alzheimer’s andother neurological disorders. Its drug candidate LX2006 cardiomyopathy helps in the treatment of Friedreich’s Ataxia & other genetic disorders. It also provides LX1004 CLN2 drug that plays an important role in treating Batten disease.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 19%News
top 43%Growth
top 47%Tech
bottom 49%Talent
bottom 40%Global
bottom 39%Funding: Raised $185M across 9 rounds · 9 rounds over 5 yrs (1.8/yr) · Last round Post IPO (Oct 2025)
News: 7 BI events in 12 mo (of 27 tracked, 4 types) · -36% YoY · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 18k LinkedIn followers — 4.6% of this cohort's audience
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Oct 2025Post IPO$10M
- May 2025Post IPO$80M
- Mar 2024Post IPO$95M
- Aug 2023Series B—
Founders & team
Investors
Sarepta, Longitude Capital, Omega Funds, PBM Capital, Lundbeck Foundation, Janus Henderson Investors
Tech stack
Apache Http ServerDreamhostGoogle AnalyticsGoogle MapsGoogle Tag ManagerJquery
#7
Series A · Ithaca, New York · founded 2021 · 10 employees$29.5Mraised▾
Series A · Ithaca, New York · founded 2021 · 10 employees
Provider of imaging solutions for microbial research and infectious diseases
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 27%Talent
top 38%Global
bottom 38%Moat
bottom 38%Market
bottom 27%Funding: Raised $29.5M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) · Last round Series A (May 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Global: Investors from 4 countries beyond United States
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- May 2026Series A$48M
- Mar 2024Series A$12.5M
- Jun 2023Seed$11.8M
Founders & team
Investors
DCVC, Lion Capital, FemHealthVentures, Germin8, Ki Tua Fund, Pangaea Ventures
#8
Series D · Brooklyn, New York · founded 2016 · 53 employees$145Mraised▾
Series D · Brooklyn, New York · founded 2016 · 53 employees
Developer of implantable bioelectronics for the treatment of neurological conditions. The company offers a motor neuroprosthesis the Stentrode which helps paralyzed patients regain the ability to communicate. Also, provides endovascular neuromodulation minimally invasive device that stimulates brain or nerve activity for the treatment of Parkinson’s disease, epilepsy, depression, and others.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 17%News
top 30%Talent
top 38%Growth
top 47%Moat
top 48%Market
bottom 46%Funding: Raised $145M across 6 rounds · 6 rounds over 5 yrs (1.2/yr) · Last round Series D (Nov 2025)
News: 3 BI events in 12 mo (of 14 tracked, 7 types) · Top themes: Funding, Capital raise
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 44k LinkedIn followers — 11.6% of this cohort's audience · 78 engagements/post (1.6× cohort median)
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · momentum +2 · hiring: R&D Manager, Senior Director, Regulatory Affairs-CA
Funding rounds
- Nov 2025Series D$200M
- Dec 2022Series C$75M
- Dec 2021Grant (prize money)$990K
- Aug 2021Grant (prize money)$10M
Founders & team
Investors
Future Fund, Khosla Ventures, Shanda, Forepont Capital Partners, ID8 Investments, General Advance
Tech stack
Apache Http ServerApple Icloud MailBarba.JsCore-JsCraft CmsGodaddy
#9
Series C · New York City, New York · founded 2021 · 22 employees$173.8Mraised▾
Series C · New York City, New York · founded 2021 · 22 employees
Developed of brain-computer interface tool for medical treatment and drug development. The company has developed a next-generation brain computing technology that has the ability to process medicine and computing. The brain implants have features for AI-based computing, device integration, and assessment of neurological illness for medicine development.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 18%Moat
top 31%Talent
top 38%Tech
top 39%AI
top 45%Growth
bottom 40%Funding: Raised $174M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series C (Nov 2025)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 38k LinkedIn followers — 10.1% of this cohort's audience · 77 engagements/post (1.6× cohort median)
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Field Clinical Specialist, VP, Market Access
Activity (LinkedIn): 2 product launches · 1 awards announced in 12 mo
Funding rounds
- Nov 2025Series C—
- Jan 2025Series C—
- Oct 2024Series C$102M
- Mar 2024Series B$27.5M
Founders & team
Investors
Steadview, B Capital, General Equity Holdings, Duquesne Family Office, Forepont Capital Partners, Mubadala
Tech stack
Apple Icloud MailBase UiCloudflareCloudflare Bot ManagementCookieyesDocusign
#10
Series B · New York City, New York · founded 2012 · 8 employees$51.2Mraised▾
Series B · New York City, New York · founded 2012 · 8 employees
Developer of immunity-inducing vaccine for the prevention and treatment of pertussis. Its lead candidate BPZE1, a live attenuated Bordetella pertussis (BP) vaccine claims to induce sterilizing mucosal immunity and long-lasting protection against pertussis disease. The candidate is nasally administered BPZE to induce both mucosal and systemic potent immune responses.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 25%Moat
top 36%Patents
top 38%Innovation
top 42%News
bottom 49%Talent
bottom 49%Funding: Raised $51.2M across 9 rounds · 9 rounds over 11 yrs (0.8/yr) · Last round Series B (Feb 2026)
Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents · Soonicorn
Patents: 24 patents matched (strict assignee match) · 18 filings since 2022 vs 1 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. hVIVO) announced in 12 mo
Funding rounds
- Feb 2026Series B$115M
- Dec 2023Series A—
- Sep 2022Series A$42.8M
- May 2022Grant (prize money)$972.1K
Founders & team
Investors
Livent, Knottpartners, NIH, HHS, RA Capital Management, Janus Henderson Investors
#11
Series C · White Plains, New York · founded 2019 · 2 employees$23Mraised▾
Series C · White Plains, New York · founded 2019 · 2 employees
Developer of a minimally invasive eye surgery technology. It offers an implantable biologic stent which is surgically implanted in tandem for increased aqueous outflow and lowering intraocular pressure.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Growth
top 15%News
top 22%Innovation
top 27%Patents
top 27%Funding
top 29%Moat
top 36%Growth: Fresh capital in last 24 mo
News: 6 BI events in 12 mo (of 10 tracked, 3 types) · +200% YoY · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo
Innovation: 62 patents (top 41% of patent-holders) · 49 filings since 2022 vs 13 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 6k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Regional Sales Director (Central) & Director of Strategic Operations
Activity (LinkedIn): 1 product launches announced in 12 mo
Funding rounds
- Apr 2026Series C$30M
- Aug 2025Series C$42M
- Feb 2025Series B$2.8M
- Aug 2022Series B$23M
Founders & team
Investors
Visionary Ventures, Sectoral, USVP, JSD I Radius Special Situations, Civilization Ventures, aMoon
#12
Seed · New York City, New York · founded 2019$86.3Mraised▾
Seed · New York City, New York · founded 2019
Developer of a platform for programmable protein interaction-based drug discovery. The company offers technologies to discover proximity modulators, including inducers, modulators, and blockers. It focuses on advancing artificial intelligence drug discovery through data generation.
Fliar Intelligence Index™ 42how this company ranks against its industry peers
Funding
top 24%Talent
top 38%AI
top 45%Tech
bottom 45%Global
bottom 33%Market
bottom 31%Funding: Raised $86.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Jan 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
AI: Product described with: artificial intelligence
Audience (LinkedIn): 12k LinkedIn followers — 3.1% of this cohort's audience
Funding rounds
- Jan 2026Seed$86.3M
Founders & team
Investors
DCVC, NVentures, Braidwell, Roivant Sciences, AIX Ventures, Yosemite
Tech stack
Google WorkspaceHeadless UiHstsNext.JsNext.Js App RouterNode.Js
Funding & investor landscape
$19.3Btotal disclosed funding
556companies funded
1,977disclosed rounds
9rounds last 90 days
Most active investors
Y Combinator13 rounds
Notable founders
Daniel Vitt
Chief Executive Officer · Immunic
Jonathon Sporn
Co-Founder & CEO · Gilgamesh
Andrew Kruegel
Co-Founder · Gilgamesh
Zachary Prensky
Founder & CEO · LB Pharmaceuticals
James Atwood
CEO · Opentrons
Jonathan Brennan-Badal
CEO · Opentrons
Nolan Townsend
CEO · LEXEO Therapeutics
Iwijn De Vlaminck
Co-Founder · Kanvas Biosciences
Matthew P Cheng
Co-Founder · Kanvas Biosciences
Rahul Sharma
Co-Founder · Synchron
Thomas Oxley
CEO · Synchron
Benjamin Rapoport
Co-Founder & CSO · Precision Neuroscience
Prism market signals · United States · country-scoped Prism corpus, 1,465,538 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United States
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and steady — the enthusiastic (strongly-positive) share moved 44% → 42% across 2008–2026.
top research entities
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
leading researchers
Stylianos Chatzimanolis · TARIK DEDOVIC · KATH-RYN ANN F. HANKINS · Christoforos Pavlou · Giannis Bolanakis · Ashley R Tetens · Tyler Findlay · Jordyn Craig-Schwartz
▲
Breakthroughs2,038 · 33%
▼ 41%→30% share
▼0.7× share momentum0 median citations71% since 2021mostly empirical
Gene-focused breakthrough research surged from 33 to 164 papers, now dominating biotech discovery activity.
rising sub-themes (early→recent)
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
Newly emergingIdentification (biology) 0→18 · Function (biology) 0→18 · Reporter gene 0→16
Landmark U1 snRNP regulates cancer cell migration and invasion in vitro · 7,224 cites
◆
Advancements2,118 · 34%
▲ 29%→35% share
▲1.2× share momentum0 median citations80% since 2021mostly empirical
Cell culture and gene expression advancements each jumped from 3 to 62 papers, signaling intensifying applied research.
rising sub-themes (early→recent)
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
Newly emergingIdentification (biology) 0→27 · Probiotic 0→24 · Cultivar 0→23
Landmark Using Deep Learning for Image-Based Plant Disease Detection · 4,262 cites
▼
Concerns1,006 · 16%
▼ 17%→15% share
▼0.9× share momentum0 median citations73% since 2021mostly empirical
Antibiotic resistance concern papers tripled from 15 to 45, reflecting sustained urgency in US biotech research.
rising sub-themes (early→recent)
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Newly emergingQuality (philosophy) 0→27 · Animal health 0→14 · Integrated pest management 0→13
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · United States
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Boston351 · +0.52
New York319 · +0.47
SF Bay Area235 · +0.57
Philadelphia115 · +0.60
San Diego101 · +0.59
Seattle95 · +0.46
Chicago95 · +0.57
Los Angeles93 · +0.61
Pittsburgh65 · +0.54
Ann Arbor65 · +0.58
PATENT SIGNAL · United States
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
457,918 filings8,000 assigneespeak 51616/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Genentech18350
- UNIV California18093
- Regeneron Pharma16106
- Amgen10600
- Monsanto Technology9821
- UNIV Pennsylvania8586
- Harvard College7497
- UNIV Texas7427
Common questions
How many Life Sciences companies are there in New York, United States?
Radar tracks 1140 indexable Life Sciences companies headquartered in New York, United States that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in New York, United States?
The Life Sciences companies in New York, United States on this list have raised a combined $19.3B in disclosed equity funding across 556 funded companies.
Which is the highest-funded Life Sciences company in New York, United States?
Immunovant is the highest-funded Life Sciences company in New York, United States, with $685M in disclosed equity funding.
How many Life Sciences companies in New York, United States are funded?
556 of the 1140 Life Sciences companies in New York, United States on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in New York, United States?
5 Life Sciences companies in New York, United States on this list are valued at $1B or more.
Who are the top investors in New York, United States Life Sciences companies?
The most active investors in New York, United States Life Sciences companies on this list include HHS, Design Technologies, NIH, Alexandria, Long Island High Technology Incubator.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.